Literature DB >> 28035137

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.

D Rossille1,2, I Azzaoui1,2, A L Feldman3, M J Maurer4, G Labouré5, M Parrens5, C Pangault1,2, T M Habermann6, S M Ansell6, B K Link7, K Tarte1,2, T E Witzig6, T Lamy1,2, S L Slager4, M Roussel1,2, N Milpied5, J R Cerhan4, T Fest1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28035137      PMCID： PMC5915627          DOI： 10.1038/leu.2016.385

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

Authors:  Philippe Armand; Arnon Nagler; Edie A Weller; Steven M Devine; David E Avigan; Yi-Bin Chen; Mark S Kaminski; H Kent Holland; Jane N Winter; James R Mason; Joseph W Fay; David A Rizzieri; Chitra M Hosing; Edward D Ball; Joseph P Uberti; Hillard M Lazarus; Markus Y Mapara; Stephanie A Gregory; John M Timmerman; David Andorsky; Reuven Or; Edmund K Waller; Rinat Rotem-Yehudar; Leo I Gordon
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

2.  Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

Authors:  Marita Ziepert; Dirk Hasenclever; Evelyn Kuhnt; Bertram Glass; Norbert Schmitz; Michael Pfreundschuh; Markus Loeffler
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

3.  Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.

Authors:  Naoki Wada; Mona A A Zaki; Yumiko Hori; Koji Hashimoto; Machiko Tsukaguchi; Yoichi Tatsumi; Jun Ishikawa; Nobuhiko Tominaga; Hiroto Sakoda; Hironori Take; Mitsuru Tsudo; Maki Kuwayama; Eiichi Morii; Katsuyuki Aozasa
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

4.  T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.

Authors:  Imane Azzaoui; Fabrice Uhel; Delphine Rossille; Celine Pangault; Joelle Dulong; Jerome Le Priol; Thierry Lamy; Roch Houot; Steven Le Gouill; Guillaume Cartron; Pascal Godmer; Krimo Bouabdallah; Noel Milpied; Gandhi Damaj; Karin Tarte; Thierry Fest; Mikael Roussel
Journal:  Blood       Date:  2016-06-23       Impact factor: 22.113

5.  The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.

Authors:  R A Wilcox; K Ristow; T M Habermann; D J Inwards; I N M Micallef; P B Johnston; J P Colgan; G S Nowakowski; S M Ansell; T E Witzig; S N Markovic; L Porrata
Journal:  Leukemia       Date:  2011-05-24       Impact factor: 11.528

6.  Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.

Authors:  Dohee Kwon; Sehui Kim; Pil-Jong Kim; Heounjeong Go; Soo Jeong Nam; Jin Ho Paik; Young A Kim; Tae Min Kim; Dae Seog Heo; Chul Woo Kim; Yoon Kyung Jeon
Journal:  Histopathology       Date:  2015-12-01       Impact factor: 5.087

Review 7.  Programmed death-1 pathway in cancer and autoimmunity.

Authors:  Ariel Pedoeem; Inbar Azoulay-Alfaguter; Marianne Strazza; Gregg J Silverman; Adam Mor
Journal:  Clin Immunol       Date:  2014-04-26       Impact factor: 3.969

Review 8.  The tumour microenvironment in B cell lymphomas.

Authors:  David W Scott; Randy D Gascoyne
Journal:  Nat Rev Cancer       Date:  2014-07-10       Impact factor: 60.716

9.  Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.

Authors:  Junichi Kiyasu; Hiroaki Miyoshi; Akie Hirata; Fumiko Arakawa; Ayako Ichikawa; Daisuke Niino; Yasuo Sugita; Yuji Yufu; Ilseung Choi; Yasunobu Abe; Naokuni Uike; Koji Nagafuji; Takashi Okamura; Koichi Akashi; Ryoichi Takayanagi; Motoaki Shiratsuchi; Koichi Ohshima
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

10.  A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer.

Authors:  M J Proctor; D C McMillan; D S Morrison; C D Fletcher; P G Horgan; S J Clarke
Journal:  Br J Cancer       Date:  2012-07-24       Impact factor: 7.640
View more
  18 in total

Review 1.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

2.  High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Sehui Kim; Soo Jeong Nam; Changhee Park; Dohee Kwon; Jeemin Yim; Seung Geun Song; Chan-Young Ock; Young A Kim; Sung Hye Park; Tae Min Kim; Yoon Kyung Jeon
Journal:  Oncoimmunology       Date:  2019-06-10       Impact factor: 8.110

Review 3.  Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.

Authors:  Lorenzo Falchi
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 4.  Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond.

Authors:  Stephen M Ansell
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.

Authors:  Michael Byrne; Olalekan O Oluwole; Bipin Savani; Navneet S Majhail; Brian T Hill; Fredrick L Locke
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-04       Impact factor: 5.742

Review 6.  Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.

Authors:  Bei Hu; Ryan Jacobs; Nilanjan Ghosh
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 4.213

Review 7.  PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.

Authors:  Zijun Y Xu-Monette; Jianfeng Zhou; Ken H Young
Journal:  Blood       Date:  2017-11-08       Impact factor: 25.476

8.  Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.

Authors:  Andrew S Flies; Nicholas B Blackburn; Alan Bruce Lyons; John D Hayball; Gregory M Woods
Journal:  Front Immunol       Date:  2017-05-03       Impact factor: 7.561

Review 9.  Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.

Authors:  Marie de Charette; Roch Houot
Journal:  Haematologica       Date:  2018-07-13       Impact factor: 9.941

Review 10.  Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.

Authors:  Jun Zhang; L Jeffrey Medeiros; Ken H Young
Journal:  Front Oncol       Date:  2018-09-10       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.